Pegfilgrastim Is Indicated To Reduce The Duration Of Neutropenia And The Incidence Of Febrile Neutropenia In Patients Receiving Chemotherapy. Lupin Had Earlier Received The Usfda Acceptance For Review Of The Biologics License Application (Bla) For Its Proposed Biosimilar To Neulasta (Pegfilgrastim).Drug Maker Lupin On Tuesday Said It Has Inked A Licensing And Distribution Pact With Axantia For Pegfilgrastim, Used To Stimulate The Production Of White Blood Cells, In The Middle East And North Africa. The Mumbai-Based Drug Firm Has Entered Into A License, Supply And Technology Sharing Agreement With Axantia Holding, A Leading Pharmaceutical Company In The Middle East Region, Lupin Said In A StatementUnder The Terms Of The Agreement, Axantia Will Register, Distribute And Market Biosimilar Pegfilgrastim In Certain Territories Including Saudi Arabia, Certain Gcc Countries, Jordan, Lebanon, Iraq, Sudan, Libya And Algeria, It Added. Pegfilgrastim Is Indicated To Reduce The Duration Of Neutropenia And The Incidence Of Febrile Neutropenia In Patients Receiving Chemotherapy. Lupin Had Earlier Received The Usfda Acceptance For Review Of The Biologics License Application (Bla) For Its Proposed Biosimilar To Neulasta (Pegfilgrastim).
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!